Alginate antacid (Gaviscon DA) chewable tablets reduce esophageal acid exposure in Chinese patients with gastroesophageal reflux disease and heartburn symptoms

Aim To assess efficacy ofDA alginate-antacidchewable tablets for reducing esophageal acid exposure in Chinese patients with gastroesophageal reflux disease (GERD) Methods Forty-fourpatients reporting moderately severe heartburn symptomsunderwent two pHmonitoring visits. Treatment sequence was randomized:patients receivedDAalginate-antacid or placebo at one visit and the alternate treatment seven days later. Aftera standardizedreflux-provoking meal,patients took four tablets of DAalginate-antacid or placebo. Esophageal pH was measured for 4 h post-dosing,using an electrode positioned 5 cm above the lower esophageal sphincter.Primary endpoint: percentage of 4-hpost-dosing period with pH